# French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

> **NCT06287749** · — · RECRUITING · sponsor: **University Hospital, Montpellier** · enrollment: 37 (estimated)

## Conditions studied

- Pancreatic Cancer Resectable
- Pancreatic Ductal Adenocarcinoma
- Minimal Residual Disease
- Liquid Biopsy
- ctDNA

## Interventions

- **BIOLOGICAL:** Blood sample/Liquid Biopsy

## Key facts

- **NCT ID:** NCT06287749
- **Lead sponsor:** University Hospital, Montpellier
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-01
- **Primary completion:** 2028-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06287749

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06287749, "French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06287749. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*